Adjuvant role of anti-angiogenic drugs in the management of head and neck arteriovenous malformations

Giacomo Colletti, Pietro Dalmonte, Laura Moneghini, Daris Ferrari, Fabiana Allevi

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Arteriovenous malformations (AVMs) are high-flow vascular malformations characterised by a complex vessel network directly connecting feeding arteries and draining veins, typically featured by a natural history of progression, while spontaneous regressions are purely anecdotal.AVMs are very aggressive entities that possess a locally infiltrative behaviour like neoplasms. Complete "radical" surgical excision presents the highest chance of cure, but nowadays there is still considerable controversy on how to treat large AVMs that are not amenable of "radical" excision.The aim of this paper is to propose a different approach to treat vast AVMs that cannot be removed radically.The association of an antiangiogenic drug (to be initiated before surgery and to be continued in the post-operative period), could prevent the feared "explosive" growth of the remaining nidus after its partial removal. This could make recontouring and other "aesthetically" focused procedures feasible in these patients, with an obvious leap in their quality of life.The most promising antiangiogenic drug seems to be Thalidomide, but other drugs such as Sirolimus, VEGF pathway inhibitors, Interferon or Matrix Metalloproteinase (MMP) Inhibitors could serve the purpose just as well. Even Propranolol could prove useful in this sense as suggested by some recent researches on retinopathy of prematurity and tumour biology.

Original languageEnglish
Pages (from-to)298-302
Number of pages5
JournalMedical Hypotheses
Volume85
Issue number3
DOIs
Publication statusPublished - Sep 1 2015

Fingerprint

Angiogenesis Inhibitors
Arteriovenous Malformations
Neck
Head
Pharmaceutical Preparations
Retinopathy of Prematurity
Vascular Malformations
Thalidomide
Matrix Metalloproteinase Inhibitors
Sirolimus
Natural History
Propranolol
Interferons
Vascular Endothelial Growth Factor A
Veins
Neoplasms
Arteries
Quality of Life
Growth
Research

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Adjuvant role of anti-angiogenic drugs in the management of head and neck arteriovenous malformations. / Colletti, Giacomo; Dalmonte, Pietro; Moneghini, Laura; Ferrari, Daris; Allevi, Fabiana.

In: Medical Hypotheses, Vol. 85, No. 3, 01.09.2015, p. 298-302.

Research output: Contribution to journalArticle

Colletti, Giacomo ; Dalmonte, Pietro ; Moneghini, Laura ; Ferrari, Daris ; Allevi, Fabiana. / Adjuvant role of anti-angiogenic drugs in the management of head and neck arteriovenous malformations. In: Medical Hypotheses. 2015 ; Vol. 85, No. 3. pp. 298-302.
@article{4c2b07fecb974a6fb05e52fe25da3fa7,
title = "Adjuvant role of anti-angiogenic drugs in the management of head and neck arteriovenous malformations",
abstract = "Arteriovenous malformations (AVMs) are high-flow vascular malformations characterised by a complex vessel network directly connecting feeding arteries and draining veins, typically featured by a natural history of progression, while spontaneous regressions are purely anecdotal.AVMs are very aggressive entities that possess a locally infiltrative behaviour like neoplasms. Complete {"}radical{"} surgical excision presents the highest chance of cure, but nowadays there is still considerable controversy on how to treat large AVMs that are not amenable of {"}radical{"} excision.The aim of this paper is to propose a different approach to treat vast AVMs that cannot be removed radically.The association of an antiangiogenic drug (to be initiated before surgery and to be continued in the post-operative period), could prevent the feared {"}explosive{"} growth of the remaining nidus after its partial removal. This could make recontouring and other {"}aesthetically{"} focused procedures feasible in these patients, with an obvious leap in their quality of life.The most promising antiangiogenic drug seems to be Thalidomide, but other drugs such as Sirolimus, VEGF pathway inhibitors, Interferon or Matrix Metalloproteinase (MMP) Inhibitors could serve the purpose just as well. Even Propranolol could prove useful in this sense as suggested by some recent researches on retinopathy of prematurity and tumour biology.",
author = "Giacomo Colletti and Pietro Dalmonte and Laura Moneghini and Daris Ferrari and Fabiana Allevi",
year = "2015",
month = "9",
day = "1",
doi = "10.1016/j.mehy.2015.05.016",
language = "English",
volume = "85",
pages = "298--302",
journal = "Medical Hypotheses",
issn = "0306-9877",
publisher = "Churchill Livingstone",
number = "3",

}

TY - JOUR

T1 - Adjuvant role of anti-angiogenic drugs in the management of head and neck arteriovenous malformations

AU - Colletti, Giacomo

AU - Dalmonte, Pietro

AU - Moneghini, Laura

AU - Ferrari, Daris

AU - Allevi, Fabiana

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Arteriovenous malformations (AVMs) are high-flow vascular malformations characterised by a complex vessel network directly connecting feeding arteries and draining veins, typically featured by a natural history of progression, while spontaneous regressions are purely anecdotal.AVMs are very aggressive entities that possess a locally infiltrative behaviour like neoplasms. Complete "radical" surgical excision presents the highest chance of cure, but nowadays there is still considerable controversy on how to treat large AVMs that are not amenable of "radical" excision.The aim of this paper is to propose a different approach to treat vast AVMs that cannot be removed radically.The association of an antiangiogenic drug (to be initiated before surgery and to be continued in the post-operative period), could prevent the feared "explosive" growth of the remaining nidus after its partial removal. This could make recontouring and other "aesthetically" focused procedures feasible in these patients, with an obvious leap in their quality of life.The most promising antiangiogenic drug seems to be Thalidomide, but other drugs such as Sirolimus, VEGF pathway inhibitors, Interferon or Matrix Metalloproteinase (MMP) Inhibitors could serve the purpose just as well. Even Propranolol could prove useful in this sense as suggested by some recent researches on retinopathy of prematurity and tumour biology.

AB - Arteriovenous malformations (AVMs) are high-flow vascular malformations characterised by a complex vessel network directly connecting feeding arteries and draining veins, typically featured by a natural history of progression, while spontaneous regressions are purely anecdotal.AVMs are very aggressive entities that possess a locally infiltrative behaviour like neoplasms. Complete "radical" surgical excision presents the highest chance of cure, but nowadays there is still considerable controversy on how to treat large AVMs that are not amenable of "radical" excision.The aim of this paper is to propose a different approach to treat vast AVMs that cannot be removed radically.The association of an antiangiogenic drug (to be initiated before surgery and to be continued in the post-operative period), could prevent the feared "explosive" growth of the remaining nidus after its partial removal. This could make recontouring and other "aesthetically" focused procedures feasible in these patients, with an obvious leap in their quality of life.The most promising antiangiogenic drug seems to be Thalidomide, but other drugs such as Sirolimus, VEGF pathway inhibitors, Interferon or Matrix Metalloproteinase (MMP) Inhibitors could serve the purpose just as well. Even Propranolol could prove useful in this sense as suggested by some recent researches on retinopathy of prematurity and tumour biology.

UR - http://www.scopus.com/inward/record.url?scp=84939568026&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939568026&partnerID=8YFLogxK

U2 - 10.1016/j.mehy.2015.05.016

DO - 10.1016/j.mehy.2015.05.016

M3 - Article

C2 - 26049824

AN - SCOPUS:84939568026

VL - 85

SP - 298

EP - 302

JO - Medical Hypotheses

JF - Medical Hypotheses

SN - 0306-9877

IS - 3

ER -